LEGN
Same song, louder speakers
H.C. Wainwright basically looked at Legend Biotech and said, “Yep, still like it.” The firm repeated its Buy rating and held the $50 price target on Legend Biotech (NASDAQ: LEGN), arguing that progress in the company’s CAR-T programs keeps the story intact.
Why this matters
Legend’s stock has been trading around $21.17, so a $50 target is the kind of upside call that makes your eyebrows do a little double-take. Sure, price targets are not crystal balls, but they do tell you where at least one analyst thinks the market is underestimating the company’s pipeline.
The biotech fine print
The note leaned on a few key points:
- anito-cel is still moving through the FDA’s standard review path, with a PDUFA date of Dec. 23
- management is treating later-line treatment as the baseline case, which suggests the commercial opportunity could widen if the data and label stay friendly
- investor relations also highlighted that second- and third-line use is the fastest-growing slice of the CARVYKTI revenue mix
Big picture
This is not a fresh clinical result or an FDA win. It’s more like a bullish reminder that Legend’s cancer-treatment pipeline still has believers. For shareholders, that can help keep sentiment from slipping into full “show me” mode while the company waits for the next real catalyst.